86 Morris Avenue
At Celgene Corporation, we’re committed to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first. As a global leader in biotechnology and CAR T cell therapy, Celgene is a place where employees can make a real impact on the lives of patients with unmet medical needs in cancer and inflammatory diseases.
As we rapidly advance our next wave of innovative medicines, we announce the creation of a new global Clinical Development Organization to accelerate and optimize clinical development across our entire mid- to late-stage portfolio. Our commitments in this area will further establish the function as a center of excellence and enhance our strategic leadership in discovery, development and commercialization.
Recognized by Forbes in 2018 as a Top 10 World’s Best Employer and by Business Insider as the #3 Most Reputable Pharma Company in the World, Celgene offers a unique work environment where you can help build the business, while building your career in ways you may not have thought possible. We’re looking for innovative self-starters who want to improve the lives of patients worldwide. For more information, visit https://www.celgene.com/careers/.
CAR T cell therapy is a groundbreaking immunotherapy treatment that leverages a patient’s own immune system in fighting their cancer. Celgene is looking for dedicated people to join our team in this exciting area of cancer treatment.
1023 articles with Celgene
The FDA approval marks the first for oral ulcers associated with Behçet’s Disease and the third for Otezla.
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Celgene Selects Lead Oncology Therapeutic Candidate Under Bispecific Antibody Collaboration with Zymeworks
First of ten potential products built on Zymeworks’ proprietary AzymetricTM platform Zymeworks to receive US$7.5 million commercial license payment
POMALYST®, in combination with bortezomib and dexamethasone, provides a new medication option for patients living with multiple myeloma
Collaboration adds additional program focused on HPK1 inhibitors, potential medicines that could restore proper immune system activity in multiple tumor types
The month of July is a slow one for the U.S. Food and Drug Administration (FDA), at least in terms of scheduled approval dates. Here’s a look at the three PDUFA dates the agency has on its calendar for the month.
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes - June 28, 2019
Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.
Bristol-Myers Squibb Company provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation.
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”
Winner selected for potential of innovation to impact people with multiple sclerosis (MS) and their care partners [14-June-2019] NEW YORK , June 14, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced that Kinza K
A group of 22 individuals will embark on this challenge to raise awareness for multiple myeloma
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
A regulatory decision from the EMA is expected in the first half of 2020.
Experienced leadership team and evolved structure position company to drive in-line business, launch new products and create long-term value through broad pipeline
Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec.
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia
U.S. Food and Drug Administration grants priority review for beta-thalassemia indication and sets target action date of December 4, 2019
According to a BioSpace survey, almost 70% of respondents are likely to look for a new job in the 12 months. The question is, why? Of those planning to look for a new job, 54% said they wanted new challenges and 42% said they wanted more rewarding opportunities. How about you? Are you ready to lo...
Celgene Updated Analysis of JAKARTA2 Fedratinib Study Shows Clinically Meaningful Responses in Patients Previously Treated for Myelofibrosis with Ruxolitinib
Results were shared in a poster presentation today at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019
Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including immunomodulatory agents, proteasome inhibitors and anti-CD38 agents
The U.S. Food and Drug Administration approved Celgene’s Revlimid (lenalidomide) in combination with a rituximab product for adults with previously treated follicular lymphoma or marginal zone lymphoma. It is the first FDA-approved combination therapy for patients with these forms of non-Hodgkin...